J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025

Data Compilation
#PharmaFlow

Pipeline Prospector June 2025: Sanofi, AbbVie, Eli Lilly, BioNTech lead pharma M&A spree; BMS, Astra ink major collaborations

Stock Recap
#PipelineProspector

Isonin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

15 API Suppliers, 7 USDMF, 5 CEP/COS, 1 JDMF, 2 EU WC, 6 NDC API, 5 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

155 FDF Dossiers, 61 FDA Orange Book, 21 Europe, 3 Canada, 1 Australia, 57 South Africa, 12 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 50MG;300MG;120MG, TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SYRUP;ORAL - 50MG/5ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 12 SPI Pharma, 12 DKSH, 6 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 4 Actylis, 2 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 17 BASF, 7 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 1 Ideal Cures, 4 Ingredion Pharma Solutions, 26 Kerry, 4 Keval Exports, 1 Kima Chemical, 3 Lonza Capsugel, 18 Microlex e.U, 2 Nitika Pharmaceutical Specialities, 1 Novo Excipients, 3 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 27 Roquette, 2 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 5 Silverline Chemicals, 1 The Dow Chemical Company, 1 Ulanqab Kema New Material, 1 Valens Pharmachem, 6 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

78 Fillers, Diluents & Binders, 30 Thickeners and Stabilizers, 27 Disintegrants & Superdisintegrants, 24 Direct Compression, 23 Lubricants & Glidants, 23 Granulation, 20 Coating Systems & Additives, 20 Co-Processed Excipients, 16 Film Formers & Plasticizers, 13 Solubilizers, 13 Parenteral, 13 Taste Masking, 12 Controlled & Modified Release, 8 Topical, 8 Chewable & Orodispersible Aids, 8 Empty Capsules, 7 Rheology Modifiers, 6 Emulsifying Agents, 3 Coloring Agents, 3 API Stability Enhancers, 1 Soft Gelatin, 1 Surfactant & Foaming Agents

DIGITAL CONTENT

9 News #PharmaBuzz

9 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 22 Regulatory FDF Prices

MARKET PLACE

12 APIs, 5 FDF Dossiers

REF. STANDARDS & IMPURITIES

1 EDQM, 1 Others

ANALYTICAL

2 Analytical Methods

2 Analytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Labeler	NDC Package Code	Non Proprietary Name	Start Marketing Date	End Marketing Date	Category Code	Dosage Form (Strength)
28/06/2025	Calyx Chemicals & Pharmaceuticals	India	Calyx Chemicals & Pharmaceuticals Limited	66639-914	ISONIAZID	2009-09-24	2025-12-31	BULK INGREDIENT	POWDER (1kg/kg)
28/06/2025	Second Pharma Co	China	Second Pharma Co., Ltd.	57845-1010	Isoniazid	2025-03-18	2026-12-31	BULK INGREDIENT	POWDER (25kg/25kg)

Isonin

Isonin

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

15 API Suppliers

7 USDMF

5 CEP/COS

1 JDMF

2 EU WC

6 NDC API

5 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

155 FDF Dossiers

61 FDA Orange Book

21 Europe

3 Canada

1 Australia

57 South Africa

12 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 50MG;300MG;120MG

TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SYRUP;ORAL - 50MG/5ML

RELATED EXCIPIENT COMPANIES

2 EUROAPI

3 Rochem International Inc

12 SPI Pharma

12 DKSH

6 Faran Shimi Pharmaceutical

4 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

1 Pfanstiehl

4 ACG Worldwide

4 Actylis

2 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

2 Ashland

17 BASF

7 DFE Pharma

1 Finar

7 Gangwal Chemicals

1 Ideal Cures

4 Ingredion Pharma Solutions

26 Kerry

4 Keval Exports

1 Kima Chemical

3 Lonza Capsugel

18 Microlex e.U

2 Nitika Pharmaceutical Specialities

1 Novo Excipients

3 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qualicaps

27 Roquette

2 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

5 Silverline Chemicals

1 The Dow Chemical Company

1 Ulanqab Kema New Material

1 Valens Pharmachem

6 Vasa Pharmachem

1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

78 Fillers, Diluents & Binders

30 Thickeners and Stabilizers

27 Disintegrants & Superdisintegrants

24 Direct Compression

23 Lubricants & Glidants

TABLET;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons